Navigation Links
Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
Date:4/30/2009

DOYLESTOWN, Pa., April 30 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., www.quigleyco.com, a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) announced today that their recently completed Phase 2 double-blinded, placebo-controlled, clinical trial of diabetic peripheral neuropathy, demonstrated a significant improvement in two key measures of distal sensory nerve function in the group treated with QR333. The compound was applied topically to the feet of subjects suffering from painful diabetic neuropathy and over the course of 12 weeks, it significantly improved both maximal conduction velocity (p=0.05) and compound sensory amplitude (p=0.05) in the sural nerve. These are well established, validated and objective electrophysiologic measures of the onset and progression of diabetic nerve damage. The mean improvement in nerve conduction velocity was 1.5 m/sec, which exceeds the change considered by thought leaders to be "clinically meaningful" in clinical studies. The sural nerve carries sensation from the feet and its pathology is the fundamental cause of foot pain and ultimately foot ulcers and amputation in some diabetic subjects.

The positive findings were detected in compliant patients (approximately 50% of the original intent to treat population) who had measurable nerve activity at both the beginning and end of the study. A more conservative analysis involving approximately 65% of the randomized subjects showed a strong, but non-significant, trend toward benefit for the QR333 treated group. Other nerves evaluated for safety purposes were unaffected. The electrophysiology testing was done as a safety measure and was of interest because of the topical application of the study drug to the area of the sural nerve.

These findings necessitate a change in the potential outlook for this investigational new drug. The Diabetic Peripheral Neuropathy market has significant unmet need for rational, mechanism-based drugs. These clinically significant findings suggest disease modification in this (12 week) phase II (b) study. The Company is aware that this is a finding in a subset of the patient population.

Since the observations obtained from the study relate to positive effect on nerve functioning, we may, in the future, be focusing on a broader therapeutic area.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of an FDA approved facility to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

Important Additional Information

The Quigley Corporation ("Quigley" or the "Company") filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on April 2, 2009 in connection with the 2009 Annual Meeting of Stockholders and began the process of mailing the definitive proxy statement and a WHITE proxy card to stockholders. The Company's stockholders are strongly advised to read Quigley's proxy statement as it contains important information. Stockholders may obtain an additional copy of Quigley's definitive proxy statement and any other documents filed by the Company with the SEC for free at the SEC's website at http://www.sec.gov. Copies of the definitive proxy statement are available for free at http://www.amstock.com/Proxy Services/ViewMaterial.asp?Co Number=07814. In addition, copies of the Company's proxy materials may be requested at no charge by contacting MacKenzie Partners, Inc. at 1-800-322-2885 or via email at quigley@mackenziepartners.com. Detailed information regarding the names, affiliations and interests of individuals who are participants in the solicitation of proxies of Quigley's stockholders is available in Quigley's definitive proxy statement filed with SEC on April 2, 2009.

    CONTACT:  Media                       Investor Relations 
              Karen Pineman               Carl Hymans
              G.S. Schwartz & Co.         G.S. Schwartz & Co.
              212.725.4500                212.725.4500
              kpineman@schwartz.com       carlh@schwartz.com


'/>"/>
SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. University of Pennsylvania researchers find that the unexpected is a key to human learning
2. Deathways open doors to unexpected cultural practices
3. Food Allergens Show Up in Unexpected Places
4. Unexpected role: EGFR protects cancer cells from starving
5. Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter
6. An unexpected way to cause leukemia
7. Longer flu season and unexpected strains make prevention plan key
8. LA BioMed researcher says unexpected increase in cancer risk found
9. Leicester scientist announces unexpected and exciting advance in study of cancer type
10. Men Are Vein Too: Innovative Treatment Sparks Unexpected Consumer Trend
11. Health effects of pesticide mixtures: Unexpected insights from the salmon brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 2017 , ... M&S Technologies, the first name in computerized ... System® 20/20. CE Certification builds upon M&S's long-standing commitment to products and software ... ISO and proven test methods used in the field of Vision Care. Smart ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research study, ... having the skills needed to execute that strategy, and the actual success of ...
(Date:3/27/2017)... ... 27, 2017 , ... According to the American Cancer Society , the ... than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, ... to avoid this latter group, tune in to Lifestyle Magazine on April ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... British Columbia , March 27, 2017 ... Directors has appointed William "Bill" Dubiel as President and ... was also elected to the Board of Directors of ... as the Executive Chairman of LightIntegra. ... LightIntegra,s next President and Chief Executive Officer. We,ve selected ...
(Date:3/27/2017)... -- A new survey from the American Association ... Program (CBP) significantly reduced beneficiary choice and access to ... forces beneficiaries to switch to unfamiliar or unsuitable testing ... AADE,s survey is the latest in a continuous ... the inherent problems with the CBP. Last year, a ...
(Date:3/27/2017)... 2017 BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... that AGI-134, an immunotherapy for the treatment of multiple cancers, ... be featured at the upcoming American Association for Cancer ... to be held on April 1-5, 2017. ... An abstract ...
Breaking Medicine Technology: